Do analysts prefer NXL or NMTC?

NeuroOne Medical Technologies has a consensus price target of $7.33, suggesting a potential upside of 427.58%. Given NeuroOne Medical Technologies' stronger consensus rating and higher probable upside, analysts clearly believe NeuroOne Medical Technologies is more favorable than Nexalin Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NeuroOne Medical Technologies 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Do analysts recommend TMDIF or NXL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Titan Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend NXL or HSCS?

HeartSciences has a consensus price target of $8.00, indicating a potential upside of 53.85%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts clearly believe HeartSciences is more favorable than Nexalin Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer NXL or ICU?

SeaStar Medical has a consensus price target of $8.00, indicating a potential upside of 125.99%. Given SeaStar Medical's stronger consensus rating and higher probable upside, analysts plainly believe SeaStar Medical is more favorable than Nexalin Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SeaStar Medical 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer NXL or ADGM?

Adagio Medical has a consensus target price of $3.50, indicating a potential upside of 625.39%. Given Adagio Medical's stronger consensus rating and higher probable upside, analysts clearly believe Adagio Medical is more favorable than Nexalin Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Adagio Medical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Nexalin Technology (NXL) Competitors

$4.90 -0.20 (-3.92%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$5.02 +0.12 (+2.45%)

As of 09/18/2026 07:30 PM Eastern

Compare

NXL vs. NMTC, TMDIF, HSCS, ICU, and ADGM

Should you buy Nexalin Technology stock or one of its competitors? Nexalin Technology's main competitors and comparable companies include NeuroOne Medical Technologies (NMTC), Titan Medical (TMDIF), HeartSciences (HSCS), SeaStar Medical (ICU), and Adagio Medical (ADGM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Nexalin Technology compare to NeuroOne Medical Technologies?

Nexalin Technology (NASDAQ:NXL) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Nexalin Technology has a beta of 3.95, indicating that its share price is 295% more volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market.

NeuroOne Medical Technologies has a net margin of -71.50% compared to Nexalin Technology's net margin of -4,141.94%. NeuroOne Medical Technologies' return on equity of -128.12% beat Nexalin Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-4,141.94%	-278.24%	-218.42%
NeuroOne Medical Technologies	-71.50%	-128.12%	-86.34%

NeuroOne Medical Technologies has a consensus price target of $7.33, suggesting a potential upside of 427.58%. Given NeuroOne Medical Technologies' stronger consensus rating and higher probable upside, analysts clearly believe NeuroOne Medical Technologies is more favorable than Nexalin Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, NeuroOne Medical Technologies had 2 more articles in the media than Nexalin Technology. MarketBeat recorded 2 mentions for NeuroOne Medical Technologies and 0 mentions for Nexalin Technology. NeuroOne Medical Technologies' average media sentiment score of 0.33 beat Nexalin Technology's score of 0.00 indicating that NeuroOne Medical Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Nexalin Technology	Neutral
NeuroOne Medical Technologies	Neutral

NeuroOne Medical Technologies has higher revenue and earnings than Nexalin Technology. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$300K	11.92	-$8.22M	-$14.41	N/A
NeuroOne Medical Technologies	$12.10M	1.05	-$3.61M	-$0.95	N/A

0.7% of Nexalin Technology shares are held by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 16.9% of Nexalin Technology shares are held by company insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

NeuroOne Medical Technologies beats Nexalin Technology on 12 of the 16 factors compared between the two stocks.

How does Nexalin Technology compare to Titan Medical?

Titan Medical (NASDAQ:TMDIF) and Nexalin Technology (NASDAQ:NXL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Titan Medical has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market. Comparatively, Nexalin Technology has a beta of 3.95, meaning that its share price is 295% more volatile than the broader market.

In the previous week, Titan Medical's average media sentiment score of 0.00 equaled Nexalin Technology'saverage media sentiment score.

Company	Overall Sentiment
Titan Medical	Neutral
Nexalin Technology	Neutral

Titan Medical has higher revenue and earnings than Nexalin Technology. Nexalin Technology is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Titan Medical	$17.63M	0.74	$6.95M	$0.05	2.30
Nexalin Technology	$300K	11.92	-$8.22M	-$14.41	N/A

0.0% of Titan Medical shares are owned by institutional investors. Comparatively, 0.7% of Nexalin Technology shares are owned by institutional investors. 0.0% of Titan Medical shares are owned by insiders. Comparatively, 16.9% of Nexalin Technology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Titan Medical has a net margin of 0.00% compared to Nexalin Technology's net margin of -4,141.94%. Titan Medical's return on equity of -82.31% beat Nexalin Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Titan Medical	N/A	-82.31%	-51.47%
Nexalin Technology	-4,141.94%	-278.24%	-218.42%

Summary

Titan Medical beats Nexalin Technology on 7 of the 12 factors compared between the two stocks.

How does Nexalin Technology compare to HeartSciences?

Nexalin Technology (NASDAQ:NXL) and HeartSciences (NASDAQ:HSCS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

HeartSciences has a consensus price target of $8.00, indicating a potential upside of 53.85%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts clearly believe HeartSciences is more favorable than Nexalin Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

0.7% of Nexalin Technology shares are owned by institutional investors. Comparatively, 17.2% of HeartSciences shares are owned by institutional investors. 16.9% of Nexalin Technology shares are owned by insiders. Comparatively, 4.9% of HeartSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

HeartSciences has a net margin of 0.00% compared to Nexalin Technology's net margin of -4,141.94%. Nexalin Technology's return on equity of -278.24% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-4,141.94%	-278.24%	-218.42%
HeartSciences	N/A	-816.90%	-181.97%

In the previous week, HeartSciences had 13 more articles in the media than Nexalin Technology. MarketBeat recorded 13 mentions for HeartSciences and 0 mentions for Nexalin Technology. HeartSciences' average media sentiment score of 0.29 beat Nexalin Technology's score of 0.00 indicating that HeartSciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Nexalin Technology	Neutral
HeartSciences	Neutral

Nexalin Technology has higher revenue and earnings than HeartSciences. HeartSciences is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$300K	11.92	-$8.22M	-$14.41	N/A
HeartSciences	N/A	N/A	-$9.14M	-$3.22	N/A

Nexalin Technology has a beta of 3.95, suggesting that its share price is 295% more volatile than the broader market. Comparatively, HeartSciences has a beta of 1.85, suggesting that its share price is 85% more volatile than the broader market.

Summary

HeartSciences beats Nexalin Technology on 9 of the 15 factors compared between the two stocks.

How does Nexalin Technology compare to SeaStar Medical?

Nexalin Technology (NASDAQ:NXL) and SeaStar Medical (NASDAQ:ICU) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

SeaStar Medical has a consensus price target of $8.00, indicating a potential upside of 125.99%. Given SeaStar Medical's stronger consensus rating and higher probable upside, analysts plainly believe SeaStar Medical is more favorable than Nexalin Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SeaStar Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Nexalin Technology has a beta of 3.95, indicating that its share price is 295% more volatile than the broader market. Comparatively, SeaStar Medical has a beta of -1.05, indicating that its share price is 205% less volatile than the broader market.

Nexalin Technology has higher earnings, but lower revenue than SeaStar Medical. SeaStar Medical is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$300K	11.92	-$8.22M	-$14.41	N/A
SeaStar Medical	$1.23M	12.69	-$12.15M	-$3.91	N/A

SeaStar Medical has a net margin of -795.51% compared to Nexalin Technology's net margin of -4,141.94%. SeaStar Medical's return on equity of -162.75% beat Nexalin Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-4,141.94%	-278.24%	-218.42%
SeaStar Medical	-795.51%	-162.75%	-109.89%

In the previous week, SeaStar Medical had 1 more articles in the media than Nexalin Technology. MarketBeat recorded 1 mentions for SeaStar Medical and 0 mentions for Nexalin Technology. Nexalin Technology's average media sentiment score of 0.00 equaled SeaStar Medical'saverage media sentiment score.

Company	Overall Sentiment
Nexalin Technology	Neutral
SeaStar Medical	Neutral

0.7% of Nexalin Technology shares are owned by institutional investors. Comparatively, 1.7% of SeaStar Medical shares are owned by institutional investors. 16.9% of Nexalin Technology shares are owned by company insiders. Comparatively, 0.7% of SeaStar Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

SeaStar Medical beats Nexalin Technology on 11 of the 15 factors compared between the two stocks.

How does Nexalin Technology compare to Adagio Medical?

Nexalin Technology (NASDAQ:NXL) and Adagio Medical (NASDAQ:ADGM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

In the previous week, Adagio Medical had 2 more articles in the media than Nexalin Technology. MarketBeat recorded 2 mentions for Adagio Medical and 0 mentions for Nexalin Technology. Nexalin Technology's average media sentiment score of 0.00 equaled Adagio Medical'saverage media sentiment score.

Company	Overall Sentiment
Nexalin Technology	Neutral
Adagio Medical	Neutral

0.7% of Nexalin Technology shares are owned by institutional investors. Comparatively, 48.1% of Adagio Medical shares are owned by institutional investors. 16.9% of Nexalin Technology shares are owned by insiders. Comparatively, 7.8% of Adagio Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Nexalin Technology has higher earnings, but lower revenue than Adagio Medical. Nexalin Technology is trading at a lower price-to-earnings ratio than Adagio Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$300K	11.92	-$8.22M	-$14.41	N/A
Adagio Medical	$600K	17.86	-$25.08M	-$1.48	N/A

Nexalin Technology has a beta of 3.95, indicating that its stock price is 295% more volatile than the broader market. Comparatively, Adagio Medical has a beta of -0.09, indicating that its stock price is 109% less volatile than the broader market.

Adagio Medical has a net margin of 0.00% compared to Nexalin Technology's net margin of -4,141.94%. Nexalin Technology's return on equity of -278.24% beat Adagio Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-4,141.94%	-278.24%	-218.42%
Adagio Medical	N/A	-661.85%	-73.35%

Adagio Medical has a consensus target price of $3.50, indicating a potential upside of 625.39%. Given Adagio Medical's stronger consensus rating and higher probable upside, analysts clearly believe Adagio Medical is more favorable than Nexalin Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Adagio Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Adagio Medical beats Nexalin Technology on 11 of the 15 factors compared between the two stocks.

Get Nexalin Technology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NXL vs. The Competition

Export

Metric	Nexalin Technology	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.60M	$5.55B	$7.24B	$13.19B
Dividend Yield	N/A	1.80%	2.57%	12.81%
P/E Ratio	-0.34	25.34	275.49	25.40
Price / Sales	11.92	72.49	646.01	89.45
Price / Cash	N/A	32.64	76.25	51.42
Price / Book	0.81	5.69	10.46	6.33
Net Income	-$8.22M	$151.55M	$3.49B	$358.33M
7 Day Performance	1.66%	0.66%	0.59%	1.12%
1 Month Performance	-50.59%	-3.33%	-1.74%	-2.39%
1 Year Performance	-82.53%	6.79%	18.13%	5.35%

Nexalin Technology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NXL Nexalin Technology	0.8544 of 5 stars	$4.90 -3.9%	N/A	-82.5%	$3.60M	$300K	N/A	8	Positive News
NMTC NeuroOne Medical Technologies	3.1629 of 5 stars	$1.69 +4.3%	$7.33 +333.9%	-75.1%	$14.75M	$12.10M	N/A	20	News Coverage Gap Up
TMDIF Titan Medical	N/A	$0.13 +10.9%	N/A	-68.5%	$14.68M	$17.63M	N/A	50	Gap Up
HSCS HeartSciences	2.2675 of 5 stars	$4.08 +9.4%	$8.00 +96.1%	+49.0%	$14.55M	N/A	N/A	10	Trending News Earnings Report Analyst Upgrade Analyst Revision High Trading Volume
ICU SeaStar Medical	2.7784 of 5 stars	$2.95 -1.0%	$8.00 +171.2%	-60.7%	$13.13M	$1.23M	N/A	2	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NXL) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nexalin Technology (NXL) Competitors

NXL vs. NMTC, TMDIF, HSCS, ICU, and ADGM

How does Nexalin Technology compare to NeuroOne Medical Technologies?

Summary

How does Nexalin Technology compare to Titan Medical?

Summary

How does Nexalin Technology compare to HeartSciences?

Summary

How does Nexalin Technology compare to SeaStar Medical?

Summary

How does Nexalin Technology compare to Adagio Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXL vs. The Competition

Nexalin Technology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nexalin Technology (NXL) Competitors

NXL vs. NMTC, TMDIF, HSCS, ICU, and ADGM

How does Nexalin Technology compare to NeuroOne Medical Technologies?

Which has more volatility and risk, NXL or NMTC?

Is NXL or NMTC more profitable?

Do analysts prefer NXL or NMTC?

Does the media refer more to NXL or NMTC?

Which has preferable valuation and earnings, NXL or NMTC?

Do insiders and institutionals hold more shares of NXL or NMTC?

Summary

How does Nexalin Technology compare to Titan Medical?

Do analysts recommend TMDIF or NXL?

Which has more volatility and risk, TMDIF or NXL?

Does the media prefer TMDIF or NXL?

Which has better earnings and valuation, TMDIF or NXL?

Do institutionals & insiders believe in TMDIF or NXL?

Is TMDIF or NXL more profitable?

Summary

How does Nexalin Technology compare to HeartSciences?

Do analysts recommend NXL or HSCS?

Do insiders and institutionals believe in NXL or HSCS?

Is NXL or HSCS more profitable?

Does the media refer more to NXL or HSCS?

Which has better valuation & earnings, NXL or HSCS?

Which has more volatility & risk, NXL or HSCS?

Summary

How does Nexalin Technology compare to SeaStar Medical?

Do analysts prefer NXL or ICU?

Which has more volatility & risk, NXL or ICU?

Which has preferable earnings & valuation, NXL or ICU?

Is NXL or ICU more profitable?

Does the media refer more to NXL or ICU?

Do institutionals & insiders believe in NXL or ICU?

Summary

How does Nexalin Technology compare to Adagio Medical?

Does the media refer more to NXL or ADGM?

Do insiders & institutionals believe in NXL or ADGM?

Which has stronger valuation & earnings, NXL or ADGM?

Which has more volatility and risk, NXL or ADGM?

Is NXL or ADGM more profitable?

Do analysts prefer NXL or ADGM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXL vs. The Competition

Nexalin Technology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools